CG Oncology Inc. (NASDAQ: CGON)
$27.8500
-0.8200 ( -2.59% ) 57.9K
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Market Data
Open
$27.8500
Previous close
$28.6700
Volume
57.9K
Market cap
$2.15B
Day range
$27.8350 - $28.9540
52 week range
$25.7700 - $50.2300
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Oct 07, 2024 |
4 | Insider transactions | 1 | Aug 30, 2024 |
8-k | 8K-related | 13 | Aug 08, 2024 |
10-q | Quarterly Reports | 63 | Aug 08, 2024 |